Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 285 entries
View as:

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04340427 Org: User:
Start: 04/10/20 End: 12/31/21 Due: 12/31/22

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT07011186 Org: User:
Start: 04/17/24 End: 10/31/26 Due: 10/31/27

A Phase II Study of Anlotinib in STS Patients

Phase: N/A Priority: Normal
NCT ID: NCT01878448 Org: User:
Start: 04/30/13 End: 04/30/17 Due: 04/30/18

Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05745363 Org: User:
Start: 02/24/23 End: 12/31/24 Due: 12/31/25

To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05982106 Org: User:
Start: 07/19/21 End: 07/28/21 Due: 07/28/22

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT03986073 Org: User:
Start: 01/01/20 End: 09/30/20 Due: 09/30/21

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04236362 Org: User:
Start: 02/27/20 End: 05/30/22 Due: 05/30/23

A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06116240 Org: User:
Start: 09/02/22 End: 12/31/23 Due: 12/31/24

A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06415903 Org: User:
Start: 06/30/24 End: 08/31/26 Due: 08/31/27

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

Phase: N/A Priority: Normal
NCT ID: NCT02449343 Org: User:
Start: 05/12/15 End: 04/30/17 Due: 04/30/18

A New Drug Used for Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03447145 Org: User:
Start: 12/26/17 End: 12/26/18 Due: 12/26/19

Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State

Phase: N/A Priority: Normal
NCT ID: NCT06768632 Org: User:
Start: 01/02/20 End: 12/30/23 Due: 12/30/24

Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients

Phase: N/A Priority: Normal
NCT ID: NCT06051565 Org: User:
Start: 11/06/21 End: 09/15/22 Due: 09/15/23

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05998941 Org: User:
Start: 08/31/23 End: 06/30/25 Due: 06/30/26

To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06522945 Org: User:
Start: 07/31/24 End: 03/31/25 Due: 03/31/26

Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05416359 Org: User:
Start: 06/30/22 End: 06/30/24 Due: 06/30/25

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03897283 Org: User:
Start: 06/20/19 End: 12/31/21 Due: 12/31/22

A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04975204 Org: User:
Start: 02/18/22 End: 08/31/24 Due: 08/31/25

Phase I Clinical Trial of TQC2731 Injection

Phase: N/A Priority: Normal
NCT ID: NCT04923607 Org: User:
Start: 06/25/21 End: 08/25/23 Due: 08/25/24

Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02072044 Org: User:
Start: 12/31/13 End: 12/31/17 Due: 12/31/18

A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT06566248 Org: User:
Start: 03/20/24 End: 03/31/25 Due: 03/31/26

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04854668 Org: User:
Start: 07/30/20 End: 12/31/25 Due: 12/31/26

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT04291248 Org: User:
Start: 03/31/20 End: 12/31/22 Due: 12/31/23

A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06344351 Org: User:
Start: 04/25/24 End: 05/20/25 Due: 05/20/26

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT04009317 Org: User:
Start: 08/13/19 End: 04/30/22 Due: 04/30/23